AjayKNookaMD

PubMed

• 15 citations
  Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
  R. Donald Harvey, Jonathan L. Kaufman, Heather R. Johnson, Ajay K. Nooka, Louette Vaughn
  Biology of Blood and Marrow Transplantation. 2013-09-01
• 10 citations
  Addressing the disparities: the approach to the African American patient with multiple myeloma.
  Manisha Bhutani, Brandon J Blue, Craig Cole, Ashraf Z Badros, Saad Z Usmani
  Blood Cancer Journal. 2023-12-18
• 320 citations
  Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
  Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, Brian Aquila, Lawrence H. Boise
  Nature Communications. 2018-12-17

Abstracts/Posters

• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all